Novo Nordisk ® nce-weekly IcoSema successfully COMBINE 1 headline trial results Change in HbA 1C Mean baseline HbA 1c : 8.2% Change in body weight Mean baseline body weight: 84.5 kg 1.9 Change from baseline (%) Change from baseline (kg) -1.6%* -0.9% IcoSema -3.7* Insulin icodec Hypoglycaemic episodes 1 (rate per patient year) IcoSema 0.14 Insulin icodec 0.63 Safety: IcoSema appeared to have safe and well-tolerated profile l 2 and 3 hypoglycaemic episodes on-treatment observation period. Randomisation; T2D: Type 2 diabetes; eatment arms with or without OADs in participants with T2D inadequately controlled with daily basal insulin
Download PDF file